Companies › Pharming Technologies
2 active drug programs in 6 registered trials: 4 Phase 2, 2 Phase 3; Immunology, Other, Neurology, Metabolic and endocrine; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Leniolisib PI3-kinase p110-delta subunit inhibitor | PIK3CD | Phase 3 | APDS; Primary Immunodeficiency Disorders (PIDs); PIDs Linked to PI3K | Nov 2026 |
| KL1333 (napazimone) LONP1 activator | LONP1 | Phase 2 | Primary Mitochondrial Disease; Mitochondrial Diseases | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06549114 | Leniolisib | Phase 2 | Primary Immunodeficiency Disorders (PIDs) | Immunology | Jun 2026 |
| NCT05438407 | Leniolisib | Phase 3 | APDS | Immunology | Nov 2026 |
| NCT05650229 | KL1333 (napazimone) | Phase 2 | Primary Mitochondrial Disease | Metabolic and endocrine | Oct 2027 |
| NCT05693129 | Leniolisib | Phase 3 | APDS | Immunology | Jul 2028 |
| NCT07514338 | KL1333 (napazimone) | Phase 2 | Mitochondrial Diseases | Neurology | Mar 2029 |
| NCT06990529 | Leniolisib | Phase 2 | PIDs Linked to PI3K | Other | Aug 2029 |
Incyte Biosciences Japan GK Incyte Kyowa Kirin Rhizen Pharmaceuticals SecuraBio
Energenesis Biomedical Laboratorios Silanes S.A. de C.V. Idorsia Pharmaceuticals PTC Therapeutics Cartesian Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.